Vaccine optimism, a calmer bond market, stimulus & Zoom in focus
Fiona Cincotta March 1, 2021 9:52 PM
US regulators approve JNJ vaccine boosting hopes of a quicker reopening. The bond market stabilises leaving US stimulus & Zoom earnings after the closing bell in focus.
Dow futures +1% at 31235
S&P futures +1% at 3848
Nasdaq futures +1.2% at 13070
FTSE +1.3% at 6568
Dax +0.9% at 13918
Euro Stoxx +1.3% at 3683
Stocks cheers the covid stimulus bill progress
US stock markets are pointing to a stronger start amid a calmer mood in the bond market and leaving the focus firmly on the US covid stimulus bill which was voted on in the House of Representatives over the week and now makes its way to the Senate where it is expected to be voted on next week.
Calmer bond market
After the bond market rout roiled financial markets last week, the picture is notably calmer this week. The 10 year US treasury yield continued to ease back from its spike higher to 1.6% last week to current levels of 1.43%.
However, speeches by Federal Reserve policymakers John Williams and Lael Brainard could well push the focus back on inflation expectations and the bond market.
Manufacturing PMIs in focus
The latest round of manufacturing PMIs have revealed broadly upbeat readings; China being the notable outlier. China’s Caixin PMI dropped to its lowest level in 9 months, although the market has shrugged off the figures given the likely distortion from the Lunar New Year.
Final PMI’s were upwardly revised across Europe with the Eurozone PMI recording its highest level since 2018 as demand surged.
US ISM manufacturing PMI is due at 15:00 UTC.
FDA approves Johnson & Johnson vaccine
Reopening optimism is adding to the upbeat mood after the US regulators approve the Johnson & Johnson one shot cobid vaccine. This is the third vaccine to receive approval stateside and has the potential to speed up the reopening process dramatically boosting risk sentiment.
One of the main beneficiaries of the pandemic has undoubtedly been Zoom. It’s share price has soared across the year from an IPO price of $36 in late 2019 and valuation of $9 billion to its current price of $370 and a valuation of $120 billion.
Revenue has also surged with Q3 seeing a 367% jump in revenue to $777.2 million, well ahead of the $694 million expected and significantly up from Q1 2020 revenues of just $328 million. The share price has been on the decline since late October’s all time high of $588 as the prospect of a successful vaccine rollout and economies reopening have raised fears that growth will slow. So guidance will be closely eyed. Expectations are for EPS $0.78c.
For more on Zoom's earnings read here
FX – EUR shrugs off accelerating German inflation
The US Dollar is extending 0.6% gains from the previous week. US Dollar Index DXY +0.15% holding above 91.00.
EUR/USD – trades depressed versus the stronger USD despite German inflation accelerating in February. German CPI February jumped 1.7% vs 1% Jan and 1.2% expected. The ECB weekly bond purchases are awaited.
Analyst Fiona Cincotta looks at EU/USD price action and levels to watch here.
GBP/USD trades -0.20% at 1.3906
EUR/USD trades -0.25% at 1.2045
Oil resumes uptrend
Oil along with other risk assets is on the rise at the start of the week owing to the upbeat market mood. Investors continue to cheer the ongoing economic recovery and the prospect of a vaccine led reopening of the economy.
Iran’s rejection of the EU and US’s invitation for direct nuclear talks is also underpinning the price. Iran refuses to restart talks without the US first halting sanctions.
Attention will turn to this week’s OPEC+ meeting with chatter surrounding a production hike increasing.
Fina Cincotta looks at the price action of WTI here.
US crude trades +2% at $62.25
Brent trades +0.4% at $64.81
14:30 Markit Manufacturing PMI
15:00 ISM manufacturing PMI
15:00 Construction spending
16:10 ECB Lagarde Speech
This report is intended for general circulation only. It should not be construed as a recommendation, or an offer (or solicitation of an offer) to buy or sell any financial products. The information provided does not take into account your specific investment objectives, financial situation or particular needs. Before you act on any recommendation that may be contained in this report, independent advice ought to be sought from a financial adviser regarding the suitability of the investment product, taking into account your specific investment objectives, financial situation or particular needs.
GAIN Capital Singapore Pte. Ltd., may distribute reports produced by its respective foreign entities or affiliates within the GAIN Capital group of companies or third parties pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed to a person in Singapore who is not an accredited investor, expert investor or an institutional investor (as defined in the Securities Futures Act), GAIN Capital Singapore Pte. Ltd. accepts legal responsibility to such persons for the contents of the report only to the extent required by law. Singapore recipients should contact GAIN Capital Singapore Pte. Ltd. at 6826 9988 for matters arising from, or in connection with the report.
In the case of all other recipients of this report, to the extent permitted by applicable laws and regulations neither GAIN Capital Singapore Pte. Ltd. nor its associated companies will be responsible or liable for any loss or damage incurred arising out of, or in connection with, any use of the information contained in this report and all such liability is hereby expressly disclaimed. No representation or warranty is made, express or implied, that the content of this report is complete or accurate.
GAIN Capital Singapore Pte. Ltd. is not under any obligation to update this report.
Trading CFDs and FX on margin carries a high level of risk that may not be suitable for some investors. Consider your investment objectives, level of experience, financial resources, risk appetite and other relevant circumstances carefully. The possibility exists that you could lose some or all of your investments, including your initial deposits. If in doubt, please seek independent expert advice. Visit cityindex.com.sg for the complete Risk Disclosure Statement.